Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5,887.67% | 238.79% | 1,845.86% | 318.22% | 84.39% |
| Total Depreciation and Amortization | -0.98% | 51.00% | 106.14% | 109.25% | 107.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,659.94% | -36.42% | 12.28% | 40.53% | 8.82% |
| Change in Net Operating Assets | 540.73% | -667.40% | 75.13% | 173.93% | -116.41% |
| Cash from Operations | 10,011.59% | 82.19% | 332.42% | 1,695.22% | -94.91% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -34.55% | 18.18% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -312.97% | -3,471.25% | -56.93% | 417.62% | 267.98% |
| Cash from Investing | -312.97% | -3,471.25% | -58.77% | 424.96% | 267.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 65.87% | 443.82% | 201.44% | 1,655.56% | -54.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,038.95% | -8.42% |
| Cash from Financing | 155.59% | 119.27% | 201.44% | -1,032.57% | -101.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.72% | -51.98% | 140.02% | 560.24% | 22.89% |